NCT01155193View on ClinicalTrials.gov

Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany

CompletedOBSERVATIONAL
Enrollment

30,804

Participants

Timeline

Start Date

September 1, 2002

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Respiratory Syncytial Virus Infections
All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01155193 - Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany | Biotech Hunter | Biotech Hunter